# Safety, Tolerability and Pharmacodynamics of SYNB1020

> **NCT03447730** · PHASE1,PHASE2 · TERMINATED · sponsor: **Synlogic** · enrollment: 23 (actual)

## Conditions studied

- Cirrhosis

## Interventions

- **DRUG:** SYNB1020
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03447730
- **Lead sponsor:** Synlogic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-19
- **Primary completion:** 2019-07-19
- **Final completion:** 2019-07-19
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Interim futility analyses identified a lack of SYNB1020 efficacy.
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447730, "Safety, Tolerability and Pharmacodynamics of SYNB1020". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03447730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*